299 related articles for article (PubMed ID: 36726975)
1. The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells.
Giannotta C; Autino F; Massaia M
Front Immunol; 2022; 13():1102471. PubMed ID: 36726975
[TBL] [Abstract][Full Text] [Related]
2. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
Kalathil SG; Thanavala Y
Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
[TBL] [Abstract][Full Text] [Related]
3. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
5. Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment.
Pramanik A; Bhattacharyya S
Life Sci; 2022 Sep; 305():120755. PubMed ID: 35780842
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC).
Giallongo C; Tibullo D; Parrinello NL; La Cava P; Di Rosa M; Bramanti V; Di Raimondo C; Conticello C; Chiarenza A; Palumbo GA; Avola R; Romano A; Di Raimondo F
Oncotarget; 2016 Dec; 7(52):85764-85775. PubMed ID: 26967390
[TBL] [Abstract][Full Text] [Related]
7. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment.
Ostrand-Rosenberg S; Beury DW; Parker KH; Horn LA
Cancer Immunol Immunother; 2020 Feb; 69(2):215-221. PubMed ID: 31501954
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
9. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
10. Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells.
Tumino N; Fiore PF; Pelosi A; Moretta L; Vacca P
Semin Immunol; 2022 Nov; 61-64():101668. PubMed ID: 36370673
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
Ostrand-Rosenberg S; Fenselau C
J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
[TBL] [Abstract][Full Text] [Related]
12. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells.
Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK
Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
14. Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission.
Tyrinova TV; Batorov EV; Aristova TA; Ushakova GY; Sizikova SA; Denisova VV; Ostanin AA; Chernykh ER
Bull Exp Biol Med; 2022 Nov; 174(1):71-75. PubMed ID: 36437327
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity.
Petersson J; Askman S; Pettersson Å; Wichert S; Hellmark T; Johansson ÅCM; Hansson M
J Immunol Res; 2021; 2021():6344344. PubMed ID: 34414242
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment, histone modifications, and myeloid-derived suppressor cells.
Tian X; Wang T; Shen H; Wang S
Cytokine Growth Factor Rev; 2023 Dec; 74():108-121. PubMed ID: 37598011
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K
Front Immunol; 2022; 13():1016059. PubMed ID: 36304465
[TBL] [Abstract][Full Text] [Related]
18. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
19. [Immune suppressive cells in the tumor microenvironment of multiple myeloma].
Shimura Y
Rinsho Ketsueki; 2023; 64(9):1099-1105. PubMed ID: 37899188
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.
Douglass SM; Fane ME; Sanseviero E; Ecker BL; Kugel CH; Behera R; Kumar V; Tcyganov EN; Yin X; Liu Q; Chhabra Y; Alicea GM; Kuruvilla R; Gabrilovich DI; Weeraratna AT
Cancer Res; 2021 Feb; 81(3):658-670. PubMed ID: 33262126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
